Details of the Drug
General Information of Drug (ID: DMX6R0H)
Drug Name |
5-phenylamino-4-cyano-3-hydroxy-isothiazole
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
CHEMBL209793; 1137-65-1; 4-Isothiazolecarbonitrile, 2,3-dihydro-3-oxo-5-(phenylamino)-; AC1MBJGN; Maybridge4_002946; 5-phenylamino-4-cyano-3-hydroxy-isothiazole; 5-anilino-3-oxo-1,2-thiazole-4-carbonitrile; Oprea1_090337; MLS000850692; SCHEMBL3527060; CTK0G1139; DTXSID30369410; CHEBI:107126; MolPort-002-913-499; GHXPCAXQBVCFNU-UHFFFAOYSA-N; HMS2799B08; HMS1529F20; CCG-1976; ZINC15924361; BDBM50187849; AKOS022652528; AKOS030549246; MCULE-9694822584; NCGC00176381-01; SMR000456709; 5-anilino-3-oxo-isothiazole-4-carbonitrile
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 217.25 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 2.1 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 2 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 2 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 4 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||